Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial
Adds comment from J&J in paragraph 6
By Brendan Pierson
Sept 10 (Reuters) -Baltimore said on Tuesday that it has settled with Walgreens WBA.O over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.
The announcement came a day after the city reached an $80 million settlement over opioids with drugmaker Teva Pharmaceutical TEVA.TA. Baltimore did not disclose the terms of its settlement with Walgreens, but the cumulative settlement amount implies that it was also $80 million.
"We are proud of our efforts to bring these companies to justice over the past several years," Baltimore Mayor Brandon Scott said in a statement.
Walgreens said in a statement: "Although Walgreens strongly disputes any liability, this settlement is in the best interests of all of our stakeholders."
The remaining defendants scheduled to face trial next week are drugmaker Johnson & Johnson JNJ.N, and distributors McKesson MCK.N and Cencora COR.N.
"We will challenge the city's claims - which have no basis in the facts or the law," J&J said in a statement, adding that it "did everything a responsible manufacturer of these important prescription pain medicines should do."
Teva, McKesson and Cencora did not immediately respond to requests for comment.
Baltimore earlier this year announced settlements with drugmaker AbbVie's ABBV.N Allergan unit, pharmacy operator CVS CVS.N and drug distributor Cardinal Health CAH.N.
Like more than 3,000 other local governments that have filed lawsuits over opioids, the city accused drugmakers of downplaying opioids' addiction risks, and distributors and pharmacies of ignoring red flags that pills were being diverted into illegal channels.
The vast majority of those cases have been settled through nationwide agreements, which now total about $46 billion.
Baltimore opted against joining those global settlements in the hopes of recovering more than it would have received through those deals. The city said that under a multi-state settlement with Teva, for example, it would have received only $11 million over 13 years.
More than 800,000 people in the United States died of opioid overdoses from 1999 through 2023, according to data from the U.S. Centers for Disease Control and Prevention.
Reporting By Brendan Pierson in New York, Editing by Alexia Garamfalvi, Jonathan Oatis and Rosalba O'Brien
Aset Terkait
Berita Terbaru
Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.
Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.
Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.
